Non-interventional, descriptive, retrospective study using data from the FranceCoag device in minor to moderate hemophilia A patients without anti-factor VIII inhibitor and on prophylactic regimen.

Progress

Inclusions closed on 09/19/2022
Analyses finalized on 03/17/2023

Presentation and objectives

The aim of this study will be to describe :
– Patient characteristics: Age, Severity/FVIII level, Time from HA diagnosis to prophylaxis, Number of target joints and bleeding/hemarthrosis in the 24 weeks prior to prophylaxis.
– Therapeutic management of patients: Reason(s) for starting prophylaxis, Treatments (episodic) in the 24 weeks prior to starting prophylaxis, Dose/frequency of prophylaxis (last prescription)

Persons concerned
Type of data collected
(*data excluding FranceCoag)

Minor and moderate hemophilia A without inhibitor

Regulatory approvals
Information note

Favourable opinion from FranceCoag’s Scientific Committee
MR004 declared to the CNIL

NI Children
NI Teenagers
NI Parents

Project sponsor (financier)

Roche Laboratory